Evidence map›Paper›PMID 39196893›Full record

ArticlePLoS pathogens2024

Determinants of pegivirus persistence, cross-species infection, and adaptation in the laboratory mouse.

Kylie Nennig, Satyapramod Murthy, Sara Maloney, Teressa M Shaw, Mark Sharobim, Eduard Matkovic, Simi Fadiran, Malorie Larsen, Mitchell D Ramuta, Arthur S Kim and 11 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Kylie NennigDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Satyapramod MurthyCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.
Sara MaloneyDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Teressa M ShawDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Mark SharobimDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Eduard MatkovicDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Simi FadiranDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Malorie LarsenDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Mitchell D RamutaDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Arthur S KimDepartment of Immunology and Microbiology, The Scripps Research Institute, San Diego, California, United States of America.
John R TeijaroDepartment of Immunology and Microbiology, The Scripps Research Institute, San Diego, California, United States of America.
Joe GroveMRC-University of Glasgow Center for Virus Research, Glasgow, United Kingdom.
Matthew StremlauBrain Science Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Himanshu SharmaCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.
Sheetal TrivediCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.
Michael J BlumDepartment of Ecology & Evolutionary Biology, University of Tennessee, Knoxville, Tennessee, United States of America.
David H O'ConnorDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Jennifer L HydeDepartment of Microbiology, University of Washington, Seattle, Washington, United States of America.
Jack T StapletonDepartment of Internal Medicine, Microbiology & Immunology, University of Iowa and Iowa City Veterans Affairs Healthcare System, Iowa City, Iowa, United States of America.
Amit KapoorCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.
Adam L BaileyDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.ORCID 0000-0002-6560-9680

Funding

Graduate Training in Cellular and Molecular Pathogenesis of Human DiseasesT32GM135119 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Zsuzsanna Fabry · 2020 to 2026
$2.2M
BLRD VA I01 BX000207NIGMS NIH HHS T32 GM135119Wellcome Trust
6 · The paper itself

Abstract

Viruses capable of causing persistent infection have developed sophisticated mechanisms for evading host immunity, and understanding these processes can reveal novel features of the host immune system. One such virus, human pegivirus (HPgV), infects ~15% of the global human population, but little is known about its biology beyond the fact that it does not cause overt disease. We passaged a pegivirus isolate of feral brown rats (RPgV) in immunodeficient laboratory mice to develop a mouse-adapted virus (maPgV) that established persistent high-titer infection in a majority of wild-type laboratory mice. maRPgV viremia was detected in the blood of mice for >300 days without apparent disease, closely recapitulating the hallmarks of HPgV infection in humans. We found a pro-viral role for type-I interferon in chronic infection; a lack of PD-1-mediated tolerance to PgV infection; and multiple mechanisms by which PgV immunity can be achieved by an immunocompetent host. These data indicate that the PgV immune evasion strategy has aspects that are both common and unique among persistent viral infections. The creation of maPgV represents the first PgV infection model in wild-type mice, thus opening the entire toolkit of the mouse host to enable further investigation of this persistent RNA virus infections.

Indexed as

FlaviviridaeFlaviviridae InfectionsAnimalsHumansImmune EvasionMiceMice, Inbred C57BLPersistent InfectionRats

Identifiers

PMID39196893
PMCPMC11355568

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.